|
|
 |
|
Viewing report
|
|
|
|
How to Enhance the Value of Antiviral Therapies through Biomarkers and Diagnostics
Decision Resources, Inc., May 2010, Pages: 23
Technologies and drugs for hard-to-treat infections are emerging as a trend in venture-backed investments. Historically, interest in biomarker and diagnostics development for infectious diseases in the developed countries has been limited to blood screening to identify disease carriers. However, recurring influenza pandemics - particularly the most recent - have generated new interest among governments as well as pharmaceutical and diagnostics companies in tackling infectious diseases globally. The focus of R&D now is novel technologies that can detect and define infectious disease pathogens faster and more accurately, distinguish different diseases and subtypes, and enable physicians to predict patient response to therapy. In this report, we focus on notable biomarker-based diagnostics opportunities in the antiviral market.
Questions answered in this report:
- HIV/AIDS continues to be the most-studied infectious disease, and physicians surveyed by Decision Resources identified HIV/AIDS as the area of the most innovative, ongoing research. However, HIV detection is only one of the drivers of diagnostics development. What other clinical imperatives are driving diagnostics development? What imperatives are driving dealmaking?
- Respiratory viruses and sexually transmitted infections (aside from HIV) offer unique opportunities to drug and diagnostics companies. How are diagnostics used to support further drug development in these areas? What perspectives do the dealmaking trends reveal?
- Approximately 73% of the infectious disease specialists surveyed by Decision Resources noted that the ability to make a differential diagnosis is an important reason for using a diagnostic test in their practices. What factors do physicians consider when determining the next steps in patient management after administering a diagnostic test? How do these factors vary across indications?
- Of the 110 antiviral biomarker/diagnostic deals we analyzed over a five-year study period, 93% were focused on diagnostics rather than on specific biomarkers. How are diagnostics addressing important unmet needs in the antiviral market?
Scope of the report:
- Primary research: Survey of 100 U.S. infectious disease specialists; their insights on unmet needs and opportunities; innovative antiviral research; pandemic preparedness.
- Dealmaking assessment: We identified 110 deals from January 2005 through January 2010 and analyzed these deals using multiple variables, such as deal type, indication, and company size.
- Indications: HIV/AIDS, hepatitis, influenza, human papillomavirus (HPV), and respiratory syncytial virus (RSV).
- Biomarker technologies: Nucleic acid testing (NAT), polymerase chain reaction (PCR), nanotechnology, immunoassay, fluorescent labeling.
Key terms for this report:
Analyte-specific reagent, Biomarker-based antivirals, H1N1 diagnostics, Infectious disease biomarkers, Infectious disease diagnostics, Influenza, Microarray technology, Multiplexing, Pandemic, Point-of-care testing, Rapid testing
Customers who bought this item also bought
Emerging Microbiology Tests and Companies Developing New Technologies and Products
Molecular Diagnostics - Technologies, Markets and Companies
Innovations in Molecular Diagnostics for Infectious Diseases
2012 Japan Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
Biomarker and Diagnostic Opportunities in Respiratory Diseases
2012 Italy Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
2012 France Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
Future US Microbiology Testing Market Outlook
|
|
|
|
